Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Avalo Therapeutics (AVTX) Assets (2016 - 2025)

Avalo Therapeutics filings provide 12 years of Assets readings, the most recent being $116.5 million for Q4 2025.

  • On a quarterly basis, Assets fell 22.74% to $116.5 million in Q4 2025 year-over-year; TTM through Dec 2025 was $116.5 million, a 22.74% decrease, with the full-year FY2025 number at $116.5 million, down 22.74% from a year prior.
  • Assets hit $116.5 million in Q4 2025 for Avalo Therapeutics, down from $125.1 million in the prior quarter.
  • In the past five years, Assets ranged from a high of $150.7 million in Q4 2024 to a low of $21.0 million in Q4 2023.
  • Median Assets over the past 5 years was $72.1 million (2021), compared with a mean of $78.3 million.
  • Biggest five-year swings in Assets: crashed 61.67% in 2022 and later skyrocketed 618.01% in 2024.
  • Avalo Therapeutics' Assets stood at $80.2 million in 2021, then crashed by 58.4% to $33.4 million in 2022, then tumbled by 37.08% to $21.0 million in 2023, then skyrocketed by 618.01% to $150.7 million in 2024, then decreased by 22.74% to $116.5 million in 2025.
  • The last three reported values for Assets were $116.5 million (Q4 2025), $125.1 million (Q3 2025), and $126.6 million (Q2 2025) per Business Quant data.